Since the loss of NF1 also causes hyperactivation of the PI3K-AKT-mTOR pathway, mTOR inhibitors (everolimus) have been used in clinical trials with very positive responses for LGGs in children with tuberous sclerosis [275]. The gene discussed is MTOR; the disease is tuberous sclerosis.